• 04 Nov 25
 

EKF Diagnostics Hldg - Total Voting Rights

EKF Diagnostics Holdings plc | EKF | 26.0 1.0 4.0% | Mkt Cap: 114.9m


 
RNS Number : 1525G
EKF Diagnostics Holdings PLC
04 November 2025
 

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Total Voting Rights

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, in accordance with the Financial Conduct Authority's Disclosure and Transparency Rules, announces that the total issued share capital of the Company consists of 449,093,790 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares"), of which 7,330,636 Ordinary Shares are held in treasury. Therefore, the total number of Ordinary Shares carrying voting rights will be 441,763,154. 

 

The above figure of 441,763,154 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Julian Baines, Executive Chair

Gavin Jones, Chief Executive Officer

 via Walbrook PR



Singer Capital Markets (Nominated Adviser & Broker)

Tel: +44 (0)20 7496 3000

Phil Davies / Oliver Platts




Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com

Paul McManus / Alice Woodings 

Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

A white machine and a blue device Description automatically generated

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

 

EKF is an AIM-listed global diagnostics business focussed on:

 

●

Point-of-Care analysers in the key areas of Hematology and Diabetes 

●

Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVREADFLESDSFFA

Research Tree RNS Article

To continue viewing this RNS article, please advise if you are one of the following:

Return to News Summary